Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H6O5S.C4H11N |
Molecular Weight | 263.311 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC.OC1=CC=C(O)C(=C1)S(O)(=O)=O
InChI
InChIKey=HBGOLJKPSFNJSD-UHFFFAOYSA-N
InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3
Molecular Formula | C4H11N |
Molecular Weight | 73.1368 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H6O5S |
Molecular Weight | 190.174 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16772766https://www.ncbi.nlm.nih.gov/pubmed/15230646 | https://www.ncbi.nlm.nih.gov/pubmed/2847355Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7319004 | https://www.ncbi.nlm.nih.gov/pubmed/15312148
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16772766https://www.ncbi.nlm.nih.gov/pubmed/15230646 | https://www.ncbi.nlm.nih.gov/pubmed/2847355
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7319004 | https://www.ncbi.nlm.nih.gov/pubmed/15312148
Calcium dobesilate (brand name Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack. This drugs also in the phase III of clinical trial is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. It was suggested, that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, and probably through activation of adenyl cyclase.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001516 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7319004 |
|||
Target ID: map04024 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2847355 |
|||
Target ID: CHEMBL2097167 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2847355 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Doxium Approved UseUnknown |
|||
Primary | Doxium Approved UseUnknown |
|||
Primary | Doxium Approved UseUnknown |
|||
Primary | DICYNONE Approved UseETHAMSYLATE is a haemostatic agent. It reduces bleeding from capillaries. Oral form prescribed for the management of blood loss in menorrhagia. Parenteral form used in surgery: prevention and treatment of pre-, per-, or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. It also is used in paediatrics for the prevention of periventricular haemorrhages in premature babies. |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions. | 1980 Sep 15 |
|
Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. | 1981 Nov 15 |
|
Effects of etamsylate on platelet functions and arachidonic acid metabolism. | 1982 Dec 27 |
|
The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury. | 2004 Aug |
Patents
Sample Use Guides
Oral. Menorrhagia - The recommended dose is 500 mg 4 times/day during menstruation. Control of hemorrhage after surgery - The recommended dose is 250-500 mg 4-6 hourly as needed.
Adults.
Presurgical: 1-2 ampoules i.v. or i.m. (250-500mg) 1 hour before surgery.
Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary.
Postsurgical: 1-2 ampoules (250-500mg) every 4-6 hours as long as the risk of bleeding persists.
Emergency cases, according to the severity of the case: 1-2 ampoules i.v. or i.m. every 4-6 hours as long as the bleeding risk persists.
Local treatment: soak a swab with the contents of one ampoule and apply to haemorrhagic area, or in the tooth socket after dental extraction. The application may be repeated if necessary; it may be associated with oral or parenteral administration.
Children.
Half the adult dose.
Neonatology: 10mg per kg body weight (0,1ml=12,5mg) injected intramuscularly within 2 hours of birth then every 6 hours for 4 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15312148
Under basal conditions, ethamsylate was unable to modify whole-blood platelet-leukocyte aggregation, but following whole-blood perfusion through a damaged vessel, ethamsylate produced a modest, but significant increase in platelet-leukocyte aggregates at concentrations 20-40 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:01:13 GMT 2023
by
admin
on
Fri Dec 15 17:01:13 GMT 2023
|
Record UNII |
24YL531VOH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B02BX01
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
||
|
WHO-VATC |
QB02BX01
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2087
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24YL531VOH
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
100000076119
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
m5047
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
Etamsylate
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
D004979
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1232131
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
C171814
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
DTXSID4045559
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
SUB11943MIG
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
4112
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
1903
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
24YL531VOH
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
1075
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
17506
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
220-090-7
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
DB13483
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY | |||
|
2624-44-4
Created by
admin on Fri Dec 15 17:01:14 GMT 2023 , Edited by admin on Fri Dec 15 17:01:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |